Type 2 Diabetes Research
Type 2 diabetes is characterized by insulin resistance and progressive β-cell dysfunction. Incretin-axis agonists are the largest commercial pharmaceutical category of the 2020s in T2D, with the long-acting GLP-1 agonist (the FDA-approved class member, the FDA-approved class member), the GLP-1 / GIP dual agonist (the FDA-approved class member), and the triple-receptor incretin agonist (investigational) representing successive generations of receptor pharmacology.
